Breast Cancer clinical trials in Mississippi

9 actively recruiting breast cancer trials at 8 sites across Mississippi.

Data from ClinicalTrials.gov · last refreshed 2026-10-12

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology

NCT ID: NCT05879926

Sites in Mississippi:

Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
Baptist Cancer Center-Grenada — Grenada, Mississippi
Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05929768

Sites in Mississippi:

Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
Baptist Cancer Center-Grenada — Grenada, Mississippi
University of Mississippi Medical Center — Jackson, Mississippi
Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06058377

Sites in Mississippi:

Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
Baptist Cancer Center-Grenada — Grenada, Mississippi
Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07391774

Sites in Mississippi:

Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
Baptist Cancer Center-Grenada — Grenada, Mississippi
Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi
Baptist Memorial Hospital and Cancer Center-Desoto — Southhaven, Mississippi

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca

NCT ID: NCT06103864

Sites in Mississippi:

Research Site — Hattiesburg, Mississippi

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.

NCT ID: NCT07085767

Sites in Mississippi:

Clinical Trial Site — Jackson, Mississippi

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…

Sponsor: Relay Therapeutics, Inc.

NCT ID: NCT06982521

Sites in Mississippi:

University of Mississippi Medical Center — Jackson, Mississippi

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in Mississippi:

Baptist Memorial Hospital and Cancer Center-Golden Triangle — Columbus, Mississippi
Baptist Cancer Center-Grenada — Grenada, Mississippi
Gulfport Memorial Hospital — Gulfport, Mississippi
Baptist Memorial Hospital and Cancer Center-Union County — New Albany, Mississippi
Baptist Memorial Hospital and Cancer Center-Oxford — Oxford, Mississippi

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Mississippi:

Massive Bio SYNERGY-AI site — Hattiesburg, Mississippi

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12